Канада - английский - Health Canada

merck canada inc - interferon alfa-2b - solution - 6000000unit - interferon alfa-2b 6000000unit - interferons

Канада - английский - Health Canada

merck canada inc - interferon alfa-2b - solution - 10000000unit - interferon alfa-2b 10000000unit - interferons

Канада - английский - Health Canada

merck canada inc - interferon alfa-2b - liquid - 15000000unit - interferon alfa-2b 15000000unit - interferons

Канада - английский - Health Canada

merck canada inc - interferon alfa-2b - liquid - 25000000unit - interferon alfa-2b 25000000unit - interferons

Канада - английский - Health Canada

merck canada inc - interferon alfa-2b - liquid - 50000000unit - interferon alfa-2b 50000000unit - interferons

Канада - английский - Health Canada

pharmaand gmbh - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

Канада - английский - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

Канада - английский - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons

Канада - английский - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons

Соединенные Штаты - английский - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - dalfampridine (unii: bh3b64okl9) (dalfampridine - unii:bh3b64okl9) - dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (ms). this was demonstrated by an increase in walking speed [see clinical studies (14)]. the use of dalfampridine extended-release tablets is contraindicated in the following conditions: there are no adequate and well-controlled studies of dalfampridine in pregnant women. administration of dalfampridine to animals during pregnancy and lactation resulted in decreased offspring viability and growth at doses similar to the maximum recommended human dose (mrhd) of 20 mg/day. dalfampridine extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in developmental toxicity studies in rats and rabbits, dalfampridine was administered orally at doses up to 10 and 5 mg/kg/day, respectively, during the period of organogenesis. these doses are approximately 5 times the mrhd on a body surface area (mg/m2 ) basis. no evidence